## CDNA: CareDx, Inc - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.2% in lower entry zone (4.0-10.0%), top quartile (88th pct) cross-sectional ranking. Short-term MRS_5 (0.4%) confirms momentum alignment. Outperforming sector by 4.5%. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($18.28)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Should CareDxâ€™s Governance Settlement and ESOP Shift Require Action From CareDx (CDNA) Investors?**
- Source: Simply Wall Street | 20251223T011014 | Neutral | Relevance: 100%
- CareDx Inc. has garnered preliminary court approval for a governance-focused settlement of shareholder derivative lawsuits and amended its bylaws to adopt a majority voting standard for director elections. This, combined with a new US$8.27 million ESOP-related shelf registration, aims to strengthen oversight and better align management with shareholder interests. While these changes are likely to be incremental in the near term, they are important for reinforcing board accountability amidst ongoing regulatory scrutiny.

**2. CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from Brokerages**
- Source: MarketBeat | 20251222T061035 | Neutral | Relevance: 100%
- CareDx, Inc. (NASDAQ:CDNA) has received a consensus "Hold" rating from nine brokerages, with an average 12-month target price of $26.67. The company recently surpassed Q3 earnings and revenue estimates, reporting $0.28 EPS against a $0.13 consensus and $100.06 million in revenue, a 20.7% year-over-year increase. Several institutional investors, including Bamco Inc. NY and Deerfield Management Company, have also increased or initiated significant positions in CDNA, indicating growing institutional interest.

**3. CareDx (CDNA): Reassessing Valuation After Governance Reform Settlement and Legal Resolution Proposal**
- Source: Sahm | 20251222T011014 | Somewhat-Bullish | Relevance: 100%
- CareDx (CDNA) has settled long-running shareholder derivative lawsuits and implemented governance reforms, leading to improved sentiment and a recent stock price rebound. The company's valuation is being reassessed with narratives suggesting it is undervalued, particularly with its AI-driven diagnostics. Despite potential challenges from Medicare reimbursement policies, growth prospects and a high discounted cash flow valuation indicate possible significant upside.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $18 | $14 | +29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-3.7% 5d) with bearish MACD, trend may be turning.
3. Elevated short interest (13.1%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 22.9x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Analyst sentiment positive (1 raises, avg +29%). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.1B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 22.9 |
| Current P/E | 29.1 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 7.9% to 4.2% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 0.4% confirms short-term momentum alignment. AM_20 at 5.2% shows strong absolute momentum above own 20MA. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.18% (CS: 89) | Strong |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 1.188x | Above |
| vs SMA200 | 1.224x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $20.02
- **Stop Loss:** $18.28 (8.7% risk)
- **Target:** $22.63 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 689
- **Position Value:** $13,793.78
- **Portfolio %:** 13.79%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*